Correvio Pharma Corp (NASDAQ:CORV) – Investment analysts at B. Riley issued their FY2018 earnings per share (EPS) estimates for shares of Correvio Pharma in a research report issued to clients and investors on Tuesday, December 4th. B. Riley analyst D. Buck expects that the company will earn ($1.02) per share for the year. B. Riley currently has a “Buy” rating and a $7.00 price objective on the stock. B. Riley also issued estimates for Correvio Pharma’s FY2019 earnings at ($0.66) EPS, FY2020 earnings at ($0.35) EPS, FY2021 earnings at $0.05 EPS and FY2022 earnings at $0.55 EPS.
Correvio Pharma (NASDAQ:CORV) last posted its earnings results on Tuesday, November 6th. The company reported ($0.20) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.20). The firm had revenue of $7.01 million for the quarter, compared to the consensus estimate of $7.55 million. Correvio Pharma had a negative net margin of 68.98% and a negative return on equity of 294.35%.
A number of other research firms also recently commented on CORV. Mackie raised shares of Correvio Pharma from a “hold” rating to a “buy” rating in a research report on Friday, October 12th. HC Wainwright set a $11.00 target price on shares of Correvio Pharma and gave the company a “buy” rating in a research report on Wednesday, November 7th. Finally, ValuEngine raised shares of Correvio Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, September 6th.
NASDAQ CORV opened at $3.47 on Thursday. The company has a current ratio of 4.05, a quick ratio of 3.46 and a debt-to-equity ratio of 4.02. The firm has a market capitalization of $122.80 million, a P/E ratio of -3.86 and a beta of -0.26. Correvio Pharma has a 12 month low of $1.31 and a 12 month high of $5.24.
Institutional investors have recently modified their holdings of the business. Worth Venture Partners LLC purchased a new position in Correvio Pharma during the 3rd quarter worth $173,000. Royce & Associates LP purchased a new position in Correvio Pharma during the 3rd quarter worth $1,025,000. ARS Investment Partners LLC purchased a new position in Correvio Pharma during the 3rd quarter worth $1,121,000. Renaissance Technologies LLC grew its position in Correvio Pharma by 22.1% during the 3rd quarter. Renaissance Technologies LLC now owns 739,248 shares of the company’s stock worth $2,972,000 after purchasing an additional 133,825 shares during the last quarter. Finally, Putnam Investments LLC purchased a new position in Correvio Pharma during the 2nd quarter worth $11,688,000. 45.88% of the stock is currently owned by institutional investors.
About Correvio Pharma
Correvio Pharma Corp., a specialty pharmaceutical company, provides various products to meet the needs of acute care physicians and patients worldwide. It develops, acquires, and commercializes various brands for the in-hospital acute care market segment. The company's portfolio of marketed brands include Xydalba (dalbavancin hydrochloride) for the treatment of acute bacterial skin and skin structure infections; Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community and hospital-acquired pneumonia; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm.
Read More: What is Compound Interest?
Receive News & Ratings for Correvio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Correvio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.